Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

0.6174 -0.5176 (-45.60%)

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

May 30, 2024

From Caribou Biosciences, Inc.

Via GlobeNewswire

Attention Biotech Investors - Stocks To Watch ↗

May 16, 2024

RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences,...

Via Benzinga

Expert Ratings For Caribou Biosciences ↗

May 16, 2024

Via Benzinga

3 Underappreciated Stocks That Could 10x in 10 Years ↗

May 12, 2024

10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line.

Via InvestorPlace

CRBU Stock Earnings: Caribou Biosciences Misses EPS, Misses Revenue for Q1 2024 ↗

May 07, 2024

CRBU stock results show that Caribou Biosciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 07, 2024

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

May 01, 2024

From Caribou Biosciences, Inc.

Via GlobeNewswire

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

April 27, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

April 24, 2024

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

April 15, 2024

From Caribou Biosciences, Inc.

Via GlobeNewswire

Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗

April 05, 2024

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday.

Via Benzinga

Topics Stocks

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

April 04, 2024

From Caribou Biosciences, Inc.

Via GlobeNewswire

Investor Sentiment Improves Following Inflation Data, Dow Jumps Over 200 Points ↗

March 13, 2024

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, but the index remained in the "Greed" zone on Tuesday.

Via Benzinga

Topics Economy Stocks

Gold Down Over 1%; ClearOne Shares Spike Higher ↗

March 12, 2024

U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up 0.74% to 39,057.10 while the NASDAQ rose 1.41% to 16,245.83. The S&P 500 also...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 12, 2024

Via Benzinga

Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 12, 2024

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.

Via Benzinga

Why Caribou Biosciences Stock Is Crashing Today ↗

March 12, 2024

Investors didn't like the clinical-stage biotech's Q4 update for one key reason.

Via The Motley Fool

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 11, 2024

From Caribou Biosciences, Inc.

Via GlobeNewswire

It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility ↗

March 11, 2024

Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23.

Via Talk Markets

Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

March 05, 2024

From Caribou Biosciences, Inc.

Via GlobeNewswire

Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold ↗

February 26, 2024

Buy this stock if you're daring, but avoid it for now if you aren't.

Via The Motley Fool

Caribou Biosciences to Participate in Upcoming Investor Conferences

February 15, 2024

From Caribou Biosciences, Inc.

Via GlobeNewswire

2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare ↗

February 12, 2024

It's less scary to take on risky investments when the market is rising.

Via The Motley Fool

3 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

January 15, 2024

These companies are still in the early innings of their growth potential.

Via The Motley Fool

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

January 07, 2024

From Caribou Biosciences, Inc.

Via GlobeNewswire

3 Gene-Editing Stocks With the Potential to Mint Millionaires ↗

December 13, 2023

Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.

Via InvestorPlace

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

December 12, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy ↗

December 07, 2023

These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.

Via InvestorPlace

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday ↗

November 17, 2023

U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday.

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.